Rifaximin-a reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. (2022)

First Author: Patel VC

Attributed to: MRC Centre for Transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2021.09.010

PubMed Identifier: 34571050

Publication URI: http://europepmc.org/abstract/MED/34571050

Type: Journal Article/Review

Volume: 76

Parent Publication: Journal of hepatology

Issue: 2

ISSN: 0168-8278